Core Viewpoint - Xi'an Yicai (688783.SH) has successfully completed its public offering, raising a total of 4.636 billion yuan, which will be fully allocated to the second phase of its silicon industry base project [1][3]. Group 1: Company Overview - Xi'an Yicai is a leading player in the 12-inch silicon wafer sector in China, marking its entry into the capital market as the first unprofitable company approved under the "Science and Technology Innovation Board Eight Articles" [3]. - The company focuses on the research, production, and sales of 12-inch silicon wafers, with a projected monthly shipment and production capacity of approximately 6% and 7% of the global market share by 2024 [3]. Group 2: Market Position and Supply Chain - In the domestic market, Xi'an Yicai has become a primary supplier for major wafer foundries and storage IDM manufacturers, ranking as the largest or second-largest supplier of 12-inch silicon wafers [5]. - The company has established a strong presence in the international market, serving major global foundries and maintaining a stable export revenue share of around 30% from 2022 to the first half of 2025 [5]. Group 3: Financial Performance - The company's revenue is projected to grow from 1.055 billion yuan in 2022 to 2.121 billion yuan in 2024, reflecting a compound annual growth rate of 41.83% [6]. - In the first half of 2025, Xi'an Yicai achieved a revenue of 1.302 billion yuan, marking a year-on-year increase of 45.99%, the best semi-annual performance since its establishment [6]. - The shipment volume is expected to surge from 2.3462 million pieces in 2022 to 6.2546 million pieces in 2024, with a compound growth rate of 63% [6]. Group 4: Future Capacity and Industry Impact - The funds raised from the IPO will be used to ensure the construction of the second factory, which, upon reaching full capacity, will enable a combined output of 1.2 million pieces per month, addressing 37% of the domestic demand for 12-inch wafers by 2026 [6]. - This expansion is anticipated to significantly alleviate the supply-demand imbalance in the domestic 12-inch silicon wafer market and enhance the competitiveness of the domestic electronic-grade silicon wafer industry [6].

Group 1 - The core viewpoint of the article highlights the approval of He Yuan Bio's registration application by the China Securities Regulatory Commission (CSRC), marking it as the first company to fully navigate the review process under the newly restarted fifth listing standard of the Sci-Tech Innovation Board [1] - The approval process for He Yuan Bio took just over ten working days, indicating a shift towards a more inclusive and efficient regulatory approval mechanism [1] - Other companies in the IPO queue under the fifth standard include Bei Xin Life, Si Zhe Rui, Heng Run Da Sheng, and Bi Bei Te, all from the pharmaceutical sector, which are unprofitable but possess core technologies [1] Group 2 - The fifth listing standard has been a crucial pathway for unprofitable hard-tech companies to access the capital market since the establishment of the Sci-Tech Innovation Board, particularly benefiting complex product technology firms with significant funding needs and long R&D cycles [2] - A total of 20 pharmaceutical companies have successfully listed under this standard, and it has now expanded to include more cutting-edge technology fields such as artificial intelligence, commercial aerospace, and low-altitude economy, facilitating easier financing for these hard-tech enterprises [2] - The acceleration of the review process is not about lowering standards but rather about reforming the system to allow truly impactful companies with significant market influence and technological achievements to list without being hindered by their unprofitability [2]